Agios Pharmaceuticals (AGIO) Competitors $42.50 -0.10 (-0.24%) As of 10:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGIO vs. VRNA, RVMD, MRUS, RNA, GRFS, CYTK, RYTM, ABVX, CRSP, and NUVLShould you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), CRISPR Therapeutics (CRSP), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Agios Pharmaceuticals vs. Its Competitors Verona Pharma PLC American Depositary Share Revolution Medicines Merus Avidity Biosciences Grifols Cytokinetics Rhythm Pharmaceuticals Abivax CRISPR Therapeutics Nuvalent Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation. Is VRNA or AGIO more profitable? Agios Pharmaceuticals has a net margin of 1,590.42% compared to Verona Pharma PLC American Depositary Share's net margin of -36.62%. Agios Pharmaceuticals' return on equity of -3.49% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets Verona Pharma PLC American Depositary Share-36.62% -21.12% -9.07% Agios Pharmaceuticals 1,590.42%-3.49%-3.23% Which has more volatility & risk, VRNA or AGIO? Verona Pharma PLC American Depositary Share has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Does the media prefer VRNA or AGIO? In the previous week, Agios Pharmaceuticals had 9 more articles in the media than Verona Pharma PLC American Depositary Share. MarketBeat recorded 18 mentions for Agios Pharmaceuticals and 9 mentions for Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.30 beat Agios Pharmaceuticals' score of 0.29 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma PLC American Depositary Share 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in VRNA or AGIO? 85.9% of Verona Pharma PLC American Depositary Share shares are owned by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are owned by company insiders. Comparatively, 4.3% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger valuation & earnings, VRNA or AGIO? Agios Pharmaceuticals has lower revenue, but higher earnings than Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma PLC American Depositary Share$42.28M217.94-$173.42M-$0.99-107.99Agios Pharmaceuticals$40.88M60.41$673.72M$11.003.86 Do analysts prefer VRNA or AGIO? Verona Pharma PLC American Depositary Share currently has a consensus price target of $109.00, indicating a potential upside of 1.95%. Agios Pharmaceuticals has a consensus price target of $56.00, indicating a potential upside of 31.77%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma PLC American Depositary Share 1 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.07Agios Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 SummaryAgios Pharmaceuticals beats Verona Pharma PLC American Depositary Share on 11 of the 16 factors compared between the two stocks. Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGIO vs. The Competition Export to ExcelMetricAgios PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.48B$3.38B$6.13B$10.61BDividend YieldN/A2.28%5.69%4.71%P/E Ratio3.8721.9385.8627.54Price / Sales60.41274.32540.53202.58Price / CashN/A47.1237.9261.55Price / Book1.5710.2012.986.78Net Income$673.72M-$52.40M$3.30B$275.79M7 Day Performance6.43%6.22%4.73%2.99%1 Month Performance17.56%15.91%9.96%9.50%1 Year Performance3.93%31.98%84.61%35.97% Agios Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGIOAgios Pharmaceuticals4.523 of 5 stars$42.50-0.2%$56.00+31.8%+5.2%$2.48B$40.88M3.87390Trending NewsAnalyst DowngradeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share1.8234 of 5 stars$106.91+0.1%$109.00+2.0%N/A$9.20B$42.28M-107.9930News CoveragePositive NewsAnalyst ForecastRVMDRevolution Medicines4.2738 of 5 stars$46.58-0.3%$74.64+60.2%-3.9%$8.73B$11.58M-10.35250Analyst ForecastMRUSMerus1.1055 of 5 stars$94.270.0%$93.12-1.2%+78.1%$7.13B$56.23M-17.1437Analyst ForecastGap UpRNAAvidity Biosciences2.2282 of 5 stars$46.18-1.7%$68.32+47.9%+4.2%$6.86B$10.90M-12.97190Analyst ForecastInsider TradeGRFSGrifols3.8651 of 5 stars$9.61-3.4%$10.30+7.2%+9.9%$6.84B$7.81B8.2123,822News CoveragePositive NewsAnalyst ForecastCYTKCytokinetics3.7388 of 5 stars$60.64+6.4%$76.64+26.4%+11.9%$6.82B$18.47M-11.89250Analyst ForecastInsider TradeGap DownRYTMRhythm Pharmaceuticals3.5235 of 5 stars$97.86-1.2%$106.64+9.0%+108.4%$6.58B$130.13M-32.51140Analyst ForecastABVXAbivax2.9216 of 5 stars$86.67+3.3%$103.29+19.2%+847.5%$6.34BN/A0.0061Analyst ForecastAnalyst RevisionHigh Trading VolumeCRSPCRISPR Therapeutics1.4625 of 5 stars$70.19+3.6%$71.50+1.9%+69.9%$6.16B$37.31M-12.93460Analyst ForecastNUVLNuvalent2.9489 of 5 stars$83.85-0.4%$118.89+41.8%-17.1%$6.07BN/A-17.1140Analyst Forecast Related Companies and Tools Related Companies Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Merus Alternatives Avidity Biosciences Alternatives Grifols Alternatives Cytokinetics Alternatives Rhythm Pharmaceuticals Alternatives Abivax Alternatives CRISPR Therapeutics Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGIO) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
